Skip to content

Arvinas ARVN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.57B+23.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$2.68B+66.8%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$1.05B+56.4%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$935.95M+37.5%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$119.96M+20.5%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$772.21M+52.8%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's additional paid-in capital?
Arvinas (ARVN) reported additional paid-in capital of $2.15B in Q1 2026.
How has Arvinas's additional paid-in capital changed year-over-year?
Arvinas's additional paid-in capital increased by 2.0% year-over-year, from $2.11B to $2.15B.
What is the long-term trend for Arvinas's additional paid-in capital?
Over 5 years (2020 to 2025), Arvinas's additional paid-in capital has grown at a 13.5% compound annual growth rate (CAGR), from $1.13B to $2.14B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.